Background Acute meningitis has a high case-fatality rate and survivors can have severe lifelong disability. We aimed to provide a comprehensive assessment of the levels and trends of global meningitis burden that could help to guide introduction, continuation, and ongoing development of vaccines and treatment programmes.
Introduction
Meningitis is an inflammatory condition involving the membranes (meninges) covering the brain and spinal cord. It can have infectious causes, such as bacteria, mycobacteria, viruses, fungi, or parasites, or be associated with autoimmunity, cancer, or reactions to medication. Risk factors that predispose individuals to meningitis and epidemics include malnutrition, 1 household over crowding, 2 HIV infection, 3 absence of immunisation, indoor air pollution, 4 and sickle cell disease. 5 Most deaths due to meningitis have infectious causes, but the clinical severity of disease varies with the causative organism. 6 Bacterial meningitis can rapidly become fatal and lead to severe disability in those who survive. Survivors might have complications, such as cognitive impairment, behavioural problems, hearing loss, motor weakness, paralysis, in coordination, or seizure disorder; although few data are available from lowresource settings, 7 one study found as many as a quarter of survivors of bacterial meningitis had neuropsychological sequelae 3-60 months after hospital discharge. 7, 8 Both bacterial and viral meningitides can place a substantial burden upon families, communities, and societies. [9] [10] [11] Although bacterial meningitis has often been associated with persistent intellectual impairment, some viral pathogens, such as parechovirus, have also been associated with impaired developmental attainment.
within each cause and across all causes, contextualises them within the sociodemographic development spectrum, and reveals the populations with the greatest need for improved meningitis prevention and treatment. Global burden from meningitis has reduced, but substantial disparities across geographic regions and age groups persist. Cause-specific estimates allowed for examination of trends in specific infections and their relationship to vaccine programmes. By quantifying long-term disability, this study also highlights the importance of health systems and societies being prepared to support survivors of meningitis.
Implications of all the available evidence
This study estimates that the largest concentration of meningitis mortality remains in the meningitis belt, which includes 26 countries across sub-Saharan Africa-from Senegal in the west to Ethiopia in the east-but many other countries also continue to have a high burden of meningitis. Vaccine coverage should be increased and existing vaccination schedules optimised to maximise population protection. Incorporating meningitis vaccines into routine vaccination schedules and ensuring these vaccines are available and administered in more countries should also be considered. Development of new vaccines and reinvestment in existing vaccines will be important to address the potential of serotype replacement in pneumococcal meningitis, to deal with epidemics, and to combat forms of meningitis that are not currently preventable. In particular, use of pneumococcal conjugate or polysaccharide vaccine in more adults and use of available or broader valency meningococcal vaccines could result in marked reductions in the burden of meningitis. Enhanced availability of appropriate antibiotics and health-care services, and low-cost diagnostics at the point of care or point of surveillance, are paramount for detecting meningitis, improving survival, and reducing disability-especially in low-resource settings where the burden of meningitis is greatest. Increased ability to detect antibiotic resistance will also become more relevant as antibiotic use and resistance continue to rise. More robust vaccine coverage and cause-specific surveillance data are crucial to improve the geographical and temporal resolution of meningitis estimates going forward.
vaccine is part of immunisation programmes across 134 countries. 15 The MenAfriVac mass vaccination campaign delivered over 270 million doses of menin gococcal A proteinpolysaccharide conjugate (MenA) vaccine to children and young adults in 21 of the 26 countries of the meningitis belt between 2010 and 2018, which resulted in a marked decline in cases of disease; 14 the meningitis belt was first defined as a "region south of the Sahara between latitudes 4 and 16⁰N" and was later expanded to include the Sahelian parts of Benin, Cameroon, Ethiopia, The Gambia, Ghana, Mali, and Senegal (appendix). 16 However, maintaining control of MenA epidemics in the long term depends on these countries implementing the vaccine routinely-a strategy taken up by only seven countries within the meningitis belt to date. 14, 17 Contemporary information on countryspecific in cidence, mortality, and longterm disease burden of meningitis by cause is needed by governments and funders to identify areas of improvement and stagnation, strengthen screening and treatment programmes, and adequately plan to support the ongoing needs of survivors. Such data can help determine countryspecific immunisation needs, and countries eligible for funding can use it to prioritise needs and assist with applications for support from Gavi, the Vaccine Alliance, UNICEF, and the Bill & Melinda Gates Foundation, among others.
The Global Burden of Diseases, Injuries, and Risk Factors (GBD) 2016 study, generated comprehensive estimates of meningitis burden by cause at the national, regional, and global level from 1990 to 2016. This report details the approach, methods, and results of the GBD 2016 analysis of the global meningitis burden to highlight levels and trends by age and geography, over time, and with respect to sociodemographic development status. The aim is to increase awareness and understanding of these estimates for stakeholders who play various roles in the identification, management, and prevention of meningitis, from researchers and clinicians to policy makers, advocates, and planners of neurological services. This report also aims to highlight some limitations and gaps in the data, with a goal of catalysing collaboration to improve future global estimates for meningitis through improved data collection, timeliness, and implementation of evidencebased policies to reduce the burden of meningitis globally.
Methods

Overview
The GBD 2016 estimation strategy for both mortality (deaths and years of life lost [YLLs] ) and nonfatal health outcomes (prevalence, incidence, and years of life lived with disability [YLDs] ), began with estimation of the epidemiology of total acute meningitis and then apportioning of that total to four subcauses. Three specific pathogens were considered separately given their relevance to public health policy, availability of effective vaccines, and comparatively robust data sources: S pneumonia (pneumococcal), N meningitides (meningococcal), and H influenzae type b. The remaining pathogens (eg, bacteria, fungi, and viruses) were grouped together as other meningitis; future analyses will consider specific pathogens for disaggregation from this category. Complete descriptions of GBD 2016 methods and inputs are available in corresponding summary publications. 18, 19 A detailed description of methods, including an analytic flowchart, data source search and extraction criteria, and model development details with respect to meningitis, is available in the appendix.
Demographics, definitions, and Socio-demographic Index
The overall goal of GBD estimation methods is to combine all available data into an internally consistent analytic framework for describing death and disability due to each cause of disease or injury. This methodological approach was applied to each of the 195 countries and territories (11 of which were analysed at the first subnational administrative level [eg, states in the USA and provinces in China]), 23 age groups, both sexes, and for each year from 1990 to 2016 (inclusive). In addition to deriving specific estimates for each age group, location, sex, and year, GBD 2016 updated the method for describing epidemiological transition that is based on the Sociodemographic Index (SDI), a composite metric based on total fertility rate, education, and percapita income, that is designed to be a summary measure of societal development and is scaled between 0 and 100. All GBD locations were grouped into SDI quintiles.
Cause-specific mortality
We estimated mortality using vital registration and verbal autopsy data that were extracted from all sources available at the time of the study and we processed the data using a set of standardised algorithms that were used across GBD 2016 to account for incompleteness, misclassifica tion, and stochastic variability (appendix). International Classification of Diseases, ninth Revision (ICD9) and tenth Revision (ICD10) codes used as the case definition for meningitis were 036-036·9/A39-A39·9 (menin gococcal meningitis), 320·0/G00·0 (H influenzae type b meningitis), 320·1/G00·1 (pneumococcal meningitis), and 047-049/320·2-322·9 (other meningitis). We then modelled all available data using cause of death ensemble modelling (CODEm) with ten candidate covariates: (1) the proportion of population living in meningitis belt, (2) proportion of children younger than 5 years who are underweight (≤2 weightforage Z scores), (3) proportion of households with improved water, (4) the Healthcare Access and Quality Index, 20 (5) health system access, a composite of vaccine coverage and pregnancy services, (6) diphtheriatetanuspertussis vaccine coverage, (7) lag distributed income (in international dollars per capita), (8) MenAfriVac vaccine coverage from 2010 to 2012, (9) improved sanitation (proportion with facilities that See Online for appendix hygienically separate human excretia from contact with humans), and (10) maternal education (years per capita). We chose the CODEm models with the highest outof sample predictive validity and then combined them with estimates from all other specific causes of death to ensure the sum matched total allcause mortality for each age group, sex, location, and year. We then assigned meningitis cause mortality in a mutually exclusive and collectively exhaustive fashion using a separate set of models of the proportion of meningitis deaths due to each cause. These models were informed by a combination of vital registration and scientific literature data identified via systematic review. YLLs were calculated by multiplying agespecific deaths and remaining global life expectancy at age of death, which was estimated by GBD 2016 to be 86·6 years at birth.
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Non-fatal health outcomes
Nonfatal health outcomes were informed by a series of complementary data sources and models. First, we gen erated internally consistent estimates of overall meningi tis incidence, prevalence, remission, and mortality using DisModMR 2.1, a Bayesian metaregression tool developed for GBD. This model was informed by published literature identified via systematic review and supplemented with inpatient hospital and claims data that were corrected for readmission rates and ICD code position (primary vs non primary) at discharge. ICDcoded hospital data served as the reference category. We then apportioned overall prevalence and incidence to underlying causes using a second set of DisModMR 2.1 proportion models informed by scientific literature and surveillance data reporting on specific infectious causes. We derived viral meningitis estimates by multiplying total meningitis and the ratio of viraltototal meningitis from inpatient hospital sources. We calculated the incidence of each longterm cause impairment combination by age group, sex, location, and year by multiplying the causespecific casefatality ratio by causespecific incidence estimates, then applying post discharge proportions of health consequences by cause, both of which were derived from a metaanalysis. 21 We paired these data with corresponding longterm mortality data to derive prevalence estimates of longterm meningitis complications for each population. We then paired and multiplied final prevalence estimates with corresponding disability weights from the GBD Disability Weights Survey 22 to calculate YLDs, which we then processed through a microsimulation framework to account for comorbidity between diseases. 19 Longterm complications of meningitis included intellectual disa bility, motor impairment, vision problems, hearing loss, epilepsy, and behavioural problems. The sum of YLLs and YLDs is disabilityadjusted lifeyears (DALYs), a composite measure of overall burden.
Risk factor attribution
We calculated attributable burden of meningitis to the risk factors low birthweight and short gestation-the only two risk factors of the 84 risk factors that met GBD 2016 causal criteria for inclusion-but only for the early and late neonatal periods as these were the only age groups for which evidence was sufficient. We quantified the population attributable fractions of low birthweight and short gestation by pairing the estimated exposure to each component with the corresponding relative risk of mortality. Details on low birthweight and short gestation estimation are in the GBD 2016 Comparative Risk Assessment paper. 
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data interpretation, or the writing of the report. All authors had full access to the data in the study and final responsibility for the decision to submit for publication.
Results
Summary results for meningitis burden are presented here. Complete results for GBD 2016 by age, sex, geography, year, and cause, including further detail not provided in this manuscript, are available in a set of interactive online visualisations called GBD Compare and are available for download from the GBD Results Tool at the Global Health Data Exchange.
3268 unique data sources were used for causespecific mortality and 1348 unique sources for the estimation of nonfatal health outcomes from meningitis. More geographical and causal detail on dataset coverage for each component of estimation is shown in the appendix. All input sources and citations for each component are available from the GBD Input Data Sources Tool. The information on all the DisModMR 2.1 models, includ ing input data and model performance, are explorable online, with corresponding information for CODEm also available.
Incident cases of meningitis globally increased from 2·50 million (2·19-2·91) in 1990 to 2·82 million (2·46-3·31) in 2016. Agestandardised incidence was highest in the meningitis belt-ie, the periSahelian countries of subSaharan Africa stretching from Senegal through South Sudan and Ethiopia (figure 1 Data are n (95% UI) or percentage change in age-standardised rates (95%UI). DALYs= disability-adjusted life-years. SDI=Socio-demographic Index. UI=uncertainty interval.
Table:
Deaths, incidence, and DALYs for meningitis in 2016 and the percentage change of age-standardised rates by location proportion of burden by age (figure 2), rates by age ( figure 3) , and changes in agestandardised rates from 1990 to 2016 (figure 4). In younger ages, meningococcal meningitis and other meningitis were the predominant cause categories in incident cases and deaths. Death rate and incidence increased, as did YLD rates, in the oldest age groups, with other meningitis and mening ococcal meningitis causing most of the burden in people 80 years and older. Global mortality decreased the most for meningococcal meningitis between 1990 and 2016 to the extent that, by 2016, the proportion of meningitis deaths in the other cause category (eg, due to Listeria, Staphylococcus, Gramnegative bacteria, fungal, and viral infections) was slightly higher in cause fraction to meningococcus. The time trend of incidence and YLDs was less stark. With decreasing incidence and YLD rates of H influenzae type b and pneumococcal meningitis, we estimated increasing rates of other meningitis, a trend that started around 2005. Although 54·0% (1·53 million [1·23-1·95]) of incident cases and 46·0% (146 322 [114 583-216 388]) of all deaths occurred in children younger than 5 years and risk of neurological disability was highest under 1 year of age, the accumulated disability burden was estimated to be highest in adolescents and young adults, with sequelae such as intellectual disability, epilepsy, vision impair ment, and motor impairment.
Increasing SDI was consistently associated with lower agestandardised DALY rates due to meningitis (figure 5). SubSaharan Africa, without exception, had higher than expected agestandardised rates of meningitis DALYs, along with the Caribbean, north Africa, and the Middle East. Central Asia, southeast Asia, and eastern Europe all had rates in the 1990s that were higher than expected but improved compared with expectation by 2016. East Asia, highincome Asia Pacific, Andean Latin America, and central Latin America were the only regions with agestandardised meningitis DALY rates that were consistently lower than expected on the basis of SDI.
5·8% (4·5-7·0) of total meningitis DALYs were attributable to low birthweight and short gestation in 2016, with the highest rates of attributable DALYs occurring in the meningitis belt countries, Burundi, Malawi, Somalia, Zambia, and Afghanistan (appendix). All attributable burden was in neonates younger than 28 days, as described in the methods section. 
Discussion
Global mortality from meningitis has declined, but substantial disparities in geographical distribution and age groups persist. In 2016, nearly 0·6% of allages deaths and close to 3% of the total in children younger than 5 years were due to meningitis ( figure 3A) . The estimates indicate that, while most incident cases are now due to infections in the other meningitis category, meningococcal infections continue to be a major cause of meningitis mortality, and most longterm disability is due to the aftereffects of pneumococcal infection. The peak age of incident meningitis is during the neonatal period, deaths are highest in children younger than 5 years, and meningitis death rates are highest in many of the same locations where overall younger than 5 years mortality is highest. 24 Rates of disability among survivors are highest in the youngest children, with a peak of prevalent disability therefore accumulating in adolescents and young adults.
On the one hand, the overall figures provided by GBD 2016 are encouraging. Agestandardised death rates due to meningitis are estimated to have dropped globally by 21·0% from 1990 to 2016. On the other hand, the corresponding figures for other vaccineresponsive and preventable pathogenbased diseases have declined (eg, measles by 93·0%, tetanus by 90·7%, and syndromebased diseases such as diarrhoea due to rotavirus by 57·9%), 18 suggesting that progress in meningitis could be substantially faster. The need for accelerated action on meningitis across the globe was recognised in a highlevel meeting in May, 2017, of more than 50 global experts, led by the Meningitis Research Foundation in collaboration with WHO, resulting in a commitment to formulate a global roadmap to defeat meningitis by 2030-a plan that required broad global commitments to strengthen systems for prevention, treatment, and surveillance. 25 Vaccination is a successful intervention for preventing meningitis. H influenzae type b meningitis has historically been a common cause of childhood hearing loss and neurological disability, affecting 15%-30% of infected children, but widespread vaccination has virtually eliminated H influenzae type b in many highincome countries 26 and has significantly reduced its incidence in many lowincome countries. 27 Widespread pneumococcal conjugate vaccination has also resulted in significant declines in invasive pneumococcal disease beyond the age groups targeted for vaccination, although postlicensure studies have detected an absence of efficacy against 28 Pneumococcal conjugate vaccine generates herd protection by preventing nasopharyngeal carriage of bacteria targeted by the vaccine in people who are immunised, although corresponding increases in nasal carriage and infection by pneumococcal serotypes that are not covered has also been widely documented, 29 suggesting that continued progress will require new and improved, highervalency vaccines or vaccines that provide universal coverage against all pneumococcal strains.
Epidemics remain a persistent threat in the meningitis belt countries of subSaharan Africa. Six of the ten countries with the highest number of meningitis deaths are in the meningitis belt, where a high incidence of meningococcal meningitis in particular has been linked to climatic factors-low humidity, dry winds, and high levels of dust in the air. 30 Mass vaccination for MenA with MenAfriVac across the belt led to steep declines in incidence of meningococcal meningitis, but epidemics due to MenC, MenW, MenX, and pneumococcus still occur. Nearly 18 000 cases of MenC were reported in Niger and Nigeria in 2017, the largest recorded epidemic. 17 As affordable MenC polysaccharide conjugate vaccines used to control epidemics are being phased out of production 31 and the potential remains high for epidemics from other serogroups, development of an affordable multivalent meningococcal vaccine is needed for mass vaccination campaigns and introduction into routine vaccination schedules.
Meningitis burden continues to be highest in resource poor settings, which is not surprising given the con fluence of factors predisposing to infections, epidemics, and poor outcomes. The proportion of survivors experiencing neurological disability is also estimated to be higher in people living in lowresource settings, 21 owing to poorer access to acute syndromic care and fewer resources available for support of survivors with neurological sequelae. Even for people who can access services, outofpocket costs are the largest source of health expenditures in many lowincome and middle income countries; meningitis can lead to catastrophic health expenditures for poor households, which can lead to delays in seeking treatment or failure to seek treatment at all. 2, 4, 5, 11, 30 In many areas of the world, especially rural areas, the capacity to do traditional diagnostic assays such as culture or PCR on CSF or blood samples is limited or nonexistent. Limitations in capacity can be especially problematic in places where other infections, such as cerebral malaria,
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Figure 4: Age-standardised rates of deaths, incidence, and YLDs due to meningitis by cause globally and for both sexes, 1990-2016 Cumulative age-standardised rates from 1990 to 2016 for cause-specific deaths (A), incidence (B), and YLDs (C) for each of the four causes of meningitis considered by GBD: meningococcal due to Neisseria meningitidis, pneumococcal due to Streptococcus pneumoniae, Haemophilus influenza type b, and other meningitis (including other bacteria, viruses, and fungi). GBD=Global Burden of Disease, Injuries, and Risk Factors Study. YLDs=years of life lived with disability. 1 9 9 0 1 9 9 1 1 9 9 2 1 9 9 3 1 9 9 4 1 9 9 5 1 9 9 6 1 9 9 7 1 9 9 8 1 9 are common and can lead to delayed or missed diagnosis of bacterial or viral meningitis with resulting mis classi fication of deaths and underrepresentation of meningitis burden. 33, 34 Additionally, diagnosis of meningitis in children, especially neonates, is difficult; the symptoms of meningitis in neonates are often subtle and mirror those seen in neonates with sepsis or other infections, resulting in potential underreporting. 35 Current assays also have important limitations: sensitivity to detect pathogens varies by pathogen; no assay is able to detect or characterise N meningitidis serogroup X; latex agglutination tests can be expensive and at times unreliable; and the widely used Pastorex agglutination test, although able to detect antigens from H influenzae type b, S pneumoniae, and N meningitidis serogroups A, C, Y, W, B, and group B Streptococcus, requires coldchain storage. 36 Countryspecific regulations that allow only already overburdened medicallytrained providers to do lumbar punctures should be reconsidered because such policies can delay needed care. 37 Efforts should be made to enhance training for other providers to search comprehensively for the source of severe acute infections and do lumbar punctures as needed. To facilitate such a change in practice, development and deployment of an affordable, sensitive, and specific rapid diagnostic test for the main bacterial meningitis pathogens-one that does not require specialised laboratory equipment or refrigeration-is urgently needed.
Acceleration of declines in meningitis burden will require improved disease surveillance and more attention to the longterm implications and impairments for survivors. Enhanced national and regional surveillance would mean that countries can monitor meningitis locally and in turn improve the precision of global estimates. Although highquality surveillance data are largely unavailable for most countries in subSaharan Africa, 38 MenAfriNet is a counterpoint that can serve as a model for other countries. Comprising Mali, Niger, Burkina Faso, and Togo-four meningitis belt countriesMenAfriNet is a network that began doing highquality casebased surveillance after MenA vaccine introduction. 39 As MenAfriNet looks to expand, data sharing is crucial both to improve estimates and to show other countries how effective and accurate surveillance can be done. Improved awareness of the disease by populations and governments is also key, as is improved support for survivors and their families. 29 Aside from GBD, no other global, causespecific meningitis estimates are available across all age groups. WHO estimates causespecific mortality due to meningitis using GBD causefractions for countries that do not have highquality vital registration data and released causespecific estimates for 2000 and 2016. Other publications reporting on meningitis epidemiology for particular pathogens or locations revealed some differences from the present analysis. First, in neonates, GBD 2016 estimated more meningococcus and less other meningitis than two studies that found most meningitis cases were due to group B Streptococcus and Escherichia coli, along with Listeria (in the highincome setting) or S pneumonia and Klebsiella (in the lowincome and middleincome setting). 41, 42 Second, combining mortality and nonfatal results to derive casefatality ratios, GBD 2016 also estimated meningococcal meningitis to have a higher The relationship between total disease burden due to all causes of meningitis, measured in DALYs, and sociodemographic development, as measured by the SDI. The average, or expected, rate of meningitis DALYs for a given level of SDI (black line) is calculated as the average meningitis DALY rate by age group, across all GBD estimation locations with that level of SDI. The observed values for each region for each year between 1990 and 2016 were aggregated from country results (coloured points). All points above the black line had higher meningitis DALY rates than expected based on SDI, while all those below the line had lower meningitis DALY rates than expected at that level of SDI. DALY=disability-adjusted life-years. 43, 44 except occasionally in the setting of epidemics. 45 These inconsistencies suggest that although casefatality rate might be higher for meningococcal meningitis overall, casefatality rate might vary by pathogen across specific age groups and geographic settings. It is important to note the comparatively high uncertainty of causespecific meningitis estimates and to acknowledge the need to ensure all available evidence on mortality is used to inform nonfatal estimates and vice versa.
This study has several limitations. First, it shares the same limitations as the overall GBD 2016 study, which are detailed elsewhere.
23,46-49 A major limitation is the relative paucity of data on distribution and severity of longterm sequelae in survivors, which for meningitis is especially notable given the high rates of neurological disability that can follow neonatal meningitis. 50 Learningrelated disabilities have not been included in GBD, potentially leading to burden underestimation in conditions such as meningitis. GBD criteria for riskoutcome pair criteria, which assess causal links from the perspective of risks rather than outcomes, are not ideal for assessing comparatively rare outcomes like meningitis. Second, causespecific meningitis estimates have a high degree of uncertainty owing to a relative paucity of pathogenspecific data. Although surveillance data can be extremely variable in quality, comprehensiveness, and completeness, if methods could be developed to identify and incorporate highquality surveillance data into GBD modelling, such data could further improve the temporal and geographical precision of overall and pathogenspecific estimates. Third, because GBD 2016 provides estimates for only three of the major bacterial causes of meningitis, important neonatal and infant pathogens, such as group B Streptococcus, Listeria, Staphylococcus, and E coli, are all grouped together; we aim to generate separate estimates for additional pathogens in future analyses. With release of a group B Streptococcus vaccine on the horizon, it will become crucial to obtain countryspecific burden estimates to guide countries in planning and implementing vaccine strate gies. 51 Meningitis due to Mycobacterium tuberculosis and HIVassociated opportunistic infections were not included because GBD classifies them with the underlying diseases. Fourth, although SDI is a useful tool for exploring epidemiologic transition, it is incomplete because it does not capture important aspects of societal function, such as political stability, gender equity, urbanicity, technology penetrance, or infrastructure, which are important social determinants of health.
Meningitis burden remains unacceptably high in 2016, despite evidence that populationlevel vaccination campaigns can effectively prevent many causes of meningitis. Detailed countryspecific meningitis burden estimates are crucial advocacy tools, empowering patients, caregivers, and civil society organisations to ask more from governments and funders to help target improved vaccination rates, to foster development ofand improve access to-rapid diagnostic tests, and to ensure that appropriate antibiotics for the most common causes of meningitis are included in the list of essential medicines. High rates of meningitis disability shine a spotlight on the need to strengthen health systems to provide additional educational support, aids and therapy for vision and hearing problems, and adaptation of the built environment for those with mobility issues. The inclusion of reliable surveillance data as inputs into GBD modelling will improve future meningitis estimates and will help prevent more people from dying from or having to live with the sequelae of meningitis.
